ramucirumab (Cyramza)

From Aaushi
Jump to navigation Jump to search

Indications

* improves median survival 5.2 vs 3.8 months with placebo

Benefit/risk

Adverse effects

Mechanism of action

More general terms

References

  1. Kelly KJ FDA Approves Drug to Treat Advanced Stomach Cancer. Physician's First Watch, April 23, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
    FDA News Release: April 21, 2014 FDA approves Cyramza for stomach cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394107.htm
  2. 2.0 2.1 2.2 2.3 Tabernero J et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015 May; 16:499 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25877855 <Internet> http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970127-0/abstract
  3. 3.0 3.1 Garon EB, Ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-673. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24933332
  4. 4.0 4.1 Perol M, Ciuleanu TE, Arrieta O et al Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo- plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer. 2016 Mar;93:95-103. Epub 2016 Jan 19. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26898621